Hybrid Metabolic Activity-Related Prognostic Model and Its Effect on Tumor in Renal Cell Carcinoma

Figure 6

The association of the hybrid metabolic activity with the tumor mutations in RCC and exploration of possible therapeutic options. (a) The mutation landscape and difference analysis of genes with high mutation rate in the renal carcinoma in high and low risk groups. B&C: violin diagrams of differences in tumor mutation burden and microsatellite instability (MSI) between high and low risk groups. (D) The linear regression analysis of the risk score and expressions of target genes related to the treatment for RCC (VEGFA, EGFR, HIF1A, HIF2A, mTOR, and CD274).

(a)

(b)

(c)

(d)